Kesatuan Eropah - Romania - EMA (European Medicines Agency)

sanofi b.v. - alfa-tirotropină - neoplasme tiroidiene - hormoni ai lobului hipofizar anterior și analogii, hipofizari și hipotalamici și analogi de hormoni - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

Kesatuan Eropah - Romania - EMA (European Medicines Agency)

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - toate celelalte produse terapeutice - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Kesatuan Eropah - Romania - EMA (European Medicines Agency)

sanofi winthrop industrie - riluzol - scleroza laterala amiotrofica - alte medicamente pentru sistemul nervos - rilutek este indicat să prelungească durata de viață sau timpul de ventilație mecanică pentru pacienții cu scleroză amiotrofică laterală (als). studiile clinice au demonstrat că rilutek prelungește supraviețuirea la pacienții cu sla. supraviețuirea a fost definit ca pacienți care au fost în viață, nu intubat pentru ventilație mecanică și traheotomie-gratuit. nu există nici o dovadă că rilutek are un efect terapeutic asupra funcției motorii, funcției pulmonare, fasciculații musculare, puterea și simptome motorii. rilutek nu a fost dovedit a fi eficiente in stadiile avansate de als. siguranța și eficacitatea rilutek a fost studiat numai in als. prin urmare, rilutek nu trebuie utilizat la pacienții cu orice altă formă de auto-boala neuronului.

Kesatuan Eropah - Romania - EMA (European Medicines Agency)

sanofi winthrop industrie - insulina glargin, lixisenatide - diabetul zaharat, tip 2 - medicamente utilizate în diabet - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.

Kesatuan Eropah - Romania - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - neoplasme colorectale - agenți antineoplazici - tratamentul cancerului colorectal metastatic (mcrc).

Romania - Romania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

smithkline beecham pharmaceuticals - marea britanie - kalii + acid clavulanicum - pulb. pt. sol. perf. - 2000mg/200mg - antibiotice beta-lactamice, peniciline peniciline in combinatii incl. inhibitori de betalactamaza

Kesatuan Eropah - Romania - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - artrita, reumatoida - imunosupresoare - kevzara în asociere cu metotrexat (mtx) este indicat pentru tratamentul moderat la sever activă artrita reumatoida (ra) la pacienţii adulţi care au răspuns inadecvat la, sau care sunt intoleranta la unul sau mai multe boli modificarea anti-reumatice droguri (dmard). kevzara poate fi administrat ca monoterapie în caz de intoleranţă la mtx sau atunci când tratamentul cu mtx este inadecvat.

Kesatuan Eropah - Romania - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenți pentru dermatită, cu excepția corticosteroizilor - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Kesatuan Eropah - Romania - EMA (European Medicines Agency)

sanofi winthrop industrie - insulina lispro - diabetul zaharat - medicamente utilizate în diabet - pentru tratamentul adulților și copiilor cu diabet zaharat care necesită insulină pentru menținerea homeostaziei normale a glucozei. insulina lispro sanofi este de asemenea indicată pentru stabilizarea inițială a diabetului zaharat.

Kesatuan Eropah - Romania - EMA (European Medicines Agency)

alnylam netherlands b.v. - patisiran de sodiu - amiloidoza familială - alte medicamente pentru sistemul nervos - onpattro este indicat pentru tratamentul ereditare transthyretin mediate de amiloidoză (hattr amiloidoza) la pacienții adulți cu etapa 1 sau 2 polineuropatie.